1. Academic Validation
  2. Belizatinib: Novel reactive intermediates and bioactivation pathways characterized by LC-MS/MS

Belizatinib: Novel reactive intermediates and bioactivation pathways characterized by LC-MS/MS

  • J Pharm Biomed Anal. 2019 Jul 15;171:132-147. doi: 10.1016/j.jpba.2019.04.006.
Mohamed W Attwa 1 Adnan A Kadi 2 Hany W Darwish 3
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; Students' University Hospital, Mansoura University, Mansoura 35516, Egypt. Electronic address: mzeidan@ksu.edu.sa.
  • 2 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
  • 3 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini St., Cairo 11562, Egypt. Electronic address: hdarwish@ksu.edu.sa.
Abstract

Belizatinib (BZB; TSR-011) is a next-generation anaplastic lymphoma kinase inhibitor that also inhibits tropomyosin-related kinases A/B/C. In this in-vitro study, we examined the formation of reactive metabolites from BZB using rat liver microsomes or human liver microsomes in the presence of a trapping agent (potassium cyanide) to generate iminium reactive intermediates. Identification of the in vitro BZB metabolites indicated that the major in-vitro metabolic reaction involved hydroxylation of the piperidine moiety. We identified eight in-vitro phase I metabolites and three iminium reactive intermediates, suggesting two possible BZB-bioactivation pathways. We propose that the tertiary nitrogen in the piperidine ring activates the attached benzyl carbon in addition to the two α carbons inside the ring. To our knowledge, this is the first report on the structural identification of reactive metabolites derived from BZB.

Keywords

Belizatinib; Benzyl carbon bioactivation; Iminium reactive intermediates; Toxicity.

Figures
Products